CD20-directed Antibody Interactions

CD20-directed Cytolytic Antibody

Arthritis, Rheumatoid

Leukemia, Lymphoid

Granulomatosis with Polyangiitis

Lymphoma, B-Cell

Lymphoma, Mantle-Cell

Microscopic Polyangiitis

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Rituximab is a genetically engineered chimeric murine/human monoclonal IgG<span class="Sub">1</span> kappa antibody directed against the CD20 antigen.  Rituximab has an approximate molecular weight of 145 kD.</p><p>Rituximab is produced by mammalian cell (Chinese Hamster Ovary) suspension culture in a nutrient medium that may contain the antibiotic gentamicin.  Gentamicin is not detectable in the final product.</p><p>RITUXAN (rituximab) injection is a sterile, preservative-free, clear, colorless solution for intravenous infusion.  RITUXAN is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials.  Each mL of solution contains 10 mg rituximab, polysorbate 80 (0.7 mg), sodium chloride (9 mg), sodium citrate dihydrate (7.35 mg), and Water for Injection, USP.  The pH is 6.5.</p></section>

Rituxan

rituximab

10 ML rituximab 10 MG/ML Injection

10 ML rituximab 10 MG/ML Injection [Rituxan]

50 ML rituximab 10 MG/ML Injection

50 ML rituximab 10 MG/ML Injection [Rituxan]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Formulary Coverage: All Indications 

Pharmacy List 

How To Order Rituxan

Billing & Coding Guide: Rheumatoid Arthritis (RA)

Billing & Coding Guide: Pemphigus Vulgaris (PV)

Billing & Coding Guide: Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA

Billing & Coding Guide: Adult Chronic Lymphoid Leukemia

Billing & Coding Guide: Pediatric Non-Hodgkin’s Lymphoma (NHL) and Acute Lymphoblastic Leukemia (ALL)

Billing & Coding Guide: Adult Non-Hodgkin’s Lymphoma (NHL)

Coverage Authorization Request 

Coverage Authorization Appeals: Rheumatoid Arthritis (RA)

Letter of Medical Necessity: Rheumatoid Arthritis (RA)

Coverage Authorization Appeals: Granulomatosis with Polyangiitis (GPA) & Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV)

Letter of Medical Necessity: Granulomatosis with Polyangiitis (GPA) & Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV)

Coverage Authorization Appeals: Non Hogkin's Lymphoma (NHL) & Chronic Lymphocytic Leukemia (CLL)

Letter of Medical Necessity: Non Hogkin's Lymphoma (NHL) & Chronic Lymphocytic Leukemia (CLL)

Prescriber Service Form: RA, GPA & MPA or PV 

Patient Consent Form 

Patient Consent Form - Spanish

Combined Prescriber Service Form and Patient Consent Form: Oncology Indications 

Genentech Patient Assitance Program Application Prescriber Form 

My Patient Solutions - HCP Portal (for managing service requests)

Prescriber Service From (Online): All Indications

Enroll in Patient Savings Program: Non Hogkin's Lymphoma (NHL) & Chronic Lymphocytic Leukemia (CLL)

Enroll in Patient Savings Program: Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA) & Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV)

About Rituxan: Pemphigus Vulgaris (PV)

Patient Resources: Pemphigus Vulgaris (PV)

Receiving Rituxan: Pemphigus Vulgaris (PV)

Preparing for Treatment: Pemphigus Vulgaris (PV)

Instructions For Use: Pemphigus Vulgaris (PV)

Patient Brochure: Pemphigus Vulgaris (PV)

About Rituxan: Rheumatoid Arthritis (RA)

Patient Stories: Rheumatoid Arthritis (RA)

FAQs: Rheumatoid Arthritis (RA) 

Receiving Rituxan: Rheumatoid Arthritis (RA)

Preparing For Treatment: Rheumatoid Arthritis 

Patient Brochure: Rheumatoid Arthritis (RA)

Instructions For Use: Rheumatoid Arthritis (RA)

About Rituxan: Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Patient Stories: Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

FAQs: Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) 

Receiving Rituxan: Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Preparing For Treatment: Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Patient Brochure: Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Instructions For Use: Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)